传承与发展丨长三角肺癌代表性论著阶段汇总走进中国科学院大学附属肿瘤医院（浙江省肿瘤医院）I期临床试验病房 Clin Lung Cancer Neoadjuvant chemotherapy followed by late-course accelerated hyperfractionated radiation therapy for locally advanced non-small-cell lung cancer: long-term results of a phase I/II clinical trial Li Zhang (2005) J Clin Oncol Randomized, placebo-controlled, phase II study of sequential Erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer Li Zhang (2009) Cancer Omitting elective nodal irradiation and irradiating postinduction versus preinduction chemotherapy tumor extent for limited-stage small cell lung cancer interim analysis of a prospective randomized noninferiority trial Li Zhang (2011) Lancet Oncol Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study Li Zhang (2011) Lancet Oncol Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial Li Zhang (2012) J Clin Oncol Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer Li Zhang (2012) J Thorac Oncol Efficacy and safety of pemetrexed maintenance therapy versus best supportive care in patients from East Asia with advanced, nonsquamous non-small cell lung cancer an exploratory subgroup analysis of a global, randomized, phase 3 clinical trial Li Zhang (2012) Asia-Pacific J Clin Oncol Phase III, randomized, open-label, first-line study in Asia of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer: evaluation of patients recruited from China Li Zhang (2012) Lancet Oncol Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial Li Zhang (2013) Lancet Oncol Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial Li Zhang (2013) Ann Oncol Pemetrexed versus gefitinib as a second-line treatment in advanced nonsquamous nonsmall-cell lung cancer patients harboring wild-type EGFR (CTONG0806): a multicenter randomized trial Li Zhang (2014) Lung Cancer A multicenter phase II study of sorafenib monotherapy in clinically selected patients with advanced lung adenocarcinoma after failure of EGFR-TKI therapy (Chinese Thoracic Oncology Group, CTONG 0805) Li Zhang (2014) Onco Targets Ther Randomized double-blind trial of prophylactic topical Evozac® Calming Skin Spray for gefitinib-associated acne-like eruption Li Zhang (2014) Plos One The efficacy and safety of Icotinib in patients with advanced non-small cell lung cancer previously treated with chemotherapy: A single-arm, multi-center, prospective study Li Zhang (2015) Sci Rep QoL analyses from INFORM study, a phase III study of gefitinib versus placebo as maintenance therapy in advanced NSCLC Li Zhang (2015) Sci Rep Randomized, multicenter study of gefitinib dose-escalation in advanced non-small-cell lung cancer patients achieved stable disease after one-month gefitinib treatment Li Zhang (2015) J Thorac Oncol Monotherapy administration of sorafenib in patients with non-small cell lung cancer (MISSION) trial A phase III, multicenter, placebo-controlled trial of Sorafenib in patients with relapsed or refractory predominantly nonsquamous non-small-cell lung cancer after 2 or 3 previous treatment regimens Li Zhang (2015) J Thorac Oncol A multicenter, open-label, randomized phase II controlled study of rh-Endostatin (Endostar) in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer Li Zhang (2015) J Thorac Oncol Final overall survival results from a phase III, randomized, placebo-controlled, parallel-group study of gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804) Li Zhang (2015) Medicine Erlotinib plus capecitabine as first-line treatment for older Chinese patients with advanced adenocarcinoma of the lung（C-TONG 0807）：an open-label，single arm，multicenter phase II study Li Zhang (2015) Lancet Respir Med Icotinib versus whole-brain irradiation in patients with EGFR-mutant non-small-cell lung cancer and multiple brain metastases (BRAIN): a multicentre, phase 3, open-label, parallel, randomised controlled trial Li Zhang (2016) Lancet Oncol Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomized controlled trial Li Zhang (2016) Ann Oncol Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trialin Lung Cancer) Li Zhang (2017) J Clin Oncol Phase III trial of Ipilimumab combined with Paclitaxel and Carboplatin in advanced squamous non-small-cell lung cancer Li Zhang (2017) Lancet Respir Med Detection of EGFR mutationsin plasma circulating tumor DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trial Li Zhang (2018) J Clin Oncol Phase Ib/II study of Capmatinib (INC280) plus Gefitinib after failure of Endothelial Growth Factor Receptor (EGFR) Inhibitor therapy in patients with EGFR-mutated, MET Factor-Dysregulated non-small-cell lung cancer Li Zhang (2018) J Thorac Oncol First-in-human phase I study of AC0010, a mutant-selective EGFR Inhibitor in non-small cell lung cancer: safety, efficacy, and potential mechanism of resistance. Li Zhang (2018) Lung Cancer Quality of life results from a randomized, double-blinded, placebo controlled, multi-center phase III trial of anlotinib in patients with advanced non-small cell lung cancer Li Zhang (2018) Lung Cancer Dynamic change of fatigue of pemetrexed maintenance treatment in the JMEN trial Li Zhang (2018) Clin Lung Cancer Afatinib as first-line treatment of older patients with EGFR mutation-positive non-small-cell lung cancer: subgroup analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 trials Li Zhang (2018) J Clin Pharmacol Pharmacokinetics of osimertinib in Chinese patients with advanced NSCLC: A phase 1 study Li Zhang (2018) J Thorac Oncol Nivolumab versus Docetaxel in a predominantly Chinese patient population with previously treated advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial Li Zhang (2019) Lancet Respir Med Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial Li Zhang (2019) Lancet Respir Med Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study Li Zhang (2019) Transl Lung Cancer Res Biosimilar candidate IBI305 pluspaclitaxel/carboplatin for the treatment of non-squamous non-small cell lung cancer Li Zhang (2020) Lung Cancer Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer: 2-year follow-up from a randomized, open-label, phase 3 study (CheckMate 078) Li Zhang (2020) Lung Cancer Phase 1/2 study of ceritinib in Chinese patients with advanced anaplastic lymphoma kinase-rearranged non-small cell lung cancer previously treated with crizotinib：Results from ASCEND-6 Li Zhang (2020) Oncologist KEYNOTE-032: A randomized phase I study of Pembrolizumab in Chinese patients with advanced non-small-cell lung cancer Li Zhang (2020) J Thorac Oncol Efficacy and safety of Sintilimab plus Pemetrexed and Platinum as first-line treatment for locally advanced or metastatic nonsquamous NSCLC: a randomized, double-blind, phase 3 study (Oncology pRogram by Innov ENT anti-PD-1-11) Li Zhang (2020) J Clin Oncol Phase III study comparing standard radiotherapy with or without weekly Oxaliplatin in treatment of locoregionally advanced nasopharyngeal carcinoma: Preliminary results Li Zhang (2005) Cancer Chemother Pharmacol Phase II clinical study of gemcitabine in the treatment of patients with advanced nasopharyngeal carcinoma after the failure of platinum-based chemotherapy Li Zhang (2008) Eur J Cancer Changes of bone resorption marker (NTX) in chemotherapy plus zoledronic acid versus chemotherapy alone for nasopharyngeal cancer patients with bone metastase Li Zhang (2011) Clin Ther Pharmacokinetics and tolerability of Vandetanib in Chinese patients with solid, malignant tumors: An open-label, phase I, rising multiple-dose study Li Zhang (2011) Oral Oncol A randomized trial of induction chemotherapy plus concurrent chemoradiotherapy versus induction chemotherapy plus radiotherapy for locoregionally advanced nasopharyngeal carcinoma Li Zhang (2012) Cancer Chemother Pharmacol Open-label, single-arm phase II study of pemetrexed in the treatment of patients with recurrent or metastatic nasopharyngeal carcinoma who have had prior platinum-based chemotherapy Li Zhang (2012) Support Care Cancer Aprepitant triple therapy for the prevention of chemotherapy-induced nausea and vomiting following high-dose cisplatin in Chinese patients: a randomized, double-blind, placebo-controlled phase III trial Li Zhang (2014) Mol Ther Multicenter randomized phase 2 clinical trial of a recombinant human Endostatin Adenovirus in patients with advanced head and neck carcinoma Li Zhang (2014) Lancet Gemcitabine plus cisplatin versus fluorouracilplus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial Li Zhang (2016) Cancer Chemother Pharmacol International randomized phase 2 study on the addition of docetaxel to the combination of cisplatin and 5‑fluorouracil in the induction treatment for nasopharyngeal carcinoma in children and adolescents Li Zhang (2016) BMC Cancer Phase I/II dose-finding study of nanoparticle albumin-bound paclitaxel (nab®-Paclitaxel) plus Cisplatin as treatment for metastatic nasopharyngeal carcinoma Li Zhang (2016) Am J Hematol Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC): A phase 1b open-label study Li Zhang (2017) Lancet Oncol Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials Li Zhang (2018) Oncologist A phase I/II open-label study of Nivolumab in previously treated advanced or recurrent nasopharyngeal carcinoma and other solid tumors Li Zhang (2019) J Thorac Oncol Predictive value of intratumoral microvascular density in patients with advanced non-small cell lung cancer receiving chemotherapy plus Bevacizumab Li Zhang (2012) OncoImmunology Upregulation of PD-L1 by EML4-ALK fusion protein mediates the immune escape in ALK positive NSCLC: Implication for optional anti-PD-1/PDL1 immunetherapy for ALK-TKIs sensitive and resistant NSCLC patients Li Zhang (2015) Mol Cancer Ther AC0010, an irreversible EGFR inhibitor selectively targeting mutated EGFR and overcoming T790M-induced resistance in animal models and lung cancer patients Li Zhang (2016) Int J Cancer Bevacizumab in combination with different platinum-based doublets in thefirst-line treatment for advanced nonsquamous non-small-cell lung cancer: A network meta-analysis Li Zhang (2016) Int J Cancer Impact of prior cancer history on the overall survival of patients newly diagnosed with cancer: A Pan-cancer analysis of the SEER database Li Zhang (2018) JAMA Oncol Concomitant genetic alterations with response to treatment and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in patients with EGFR-mutant advanced non-small cell lung cancer Li Zhang (2018) Clin Cancer Res Comprehensive genomic profiling identifies novel genetic predictors of response to Anti-PD-(L)1 therapies in non-small cell lung cancer Li Zhang (2019) Mol Cancer Intratumor heterogeneity comparison among different subtypes of non-small-cell lung cancer through multi-region tissue and matched ctDNA sequencing Li Zhang (2019) Int J Cancer Progression-free survival and one-year milestone survival as surrogates for overall survival in previously treated advanced non-small cell lung cancer Li Zhang (2019) Nat Commun The Aryl hydrocarbon receptor mediates to bacco induced PD-L1 expression and is associated with response to immunotherapy Li Zhang (2019) Nat Commun The genomic landscape of Epstein-Barr virus associated pulmonary lymphoepithelioma-likecarcinoma Li Zhang (2019) Oncologist Mutation variants and co-mutations as genomic modifiers of response to Afatinib in HER2-mutant lung adenocarcinoma Li Zhang (2019) J Thorac Oncol Conformational landscapes of HER2 exon 20 insertions explain their sensitivity to kinase inhibitors in lung adenocarcinoma Li Zhang (2020) Transl Lung Cancer Res PI3K-AKT-mTOR pathway alterations in advanced NSCLC patients after progression on EGFR-TKI and clinicalresponse to EGFR-TKI plus everolimus combination therapy Li Zhang (2020) Clin Trans Med EGFR T790M relative mutation purity predicts osimertinib treatment efficacy in non‑small cell lung cancer patients Li Zhang (2020) Clin Trans Med Pan-cancer analysis identifies TERT alterations as predictive biomarkers for immune checkpoint inhibitors treatment Li Zhang (2020) Transl Lung Cancer Res EGFR mutation genotypes affect efficacy and resistance mechanisms of osimertinib in T790M-positive NSCLC patients Li Zhang (2020) NPJ Precis Oncol PBRM1 mutation and preliminary response to immune checkpoint blockade treatment in non-small cell lung cancer Li Zhang (2020) Cancer Radiation-induced sarcoma in patients with nasopharyngeal carcinoma Li Zhang (2010) Eur J Cancer Changes of bone resorption marker (NTX) in chemotherapy plus zoledronic acid versus chemotherapy alone for nasopharyngeal cancer patients with bone metastases Li Zhang (2011) Cancer Plasma Epstein-Barr virus DNA level strongly predicts survival in metastatic/ recurrent nasopharyngeal carcinoma treated with palliative chemotherapy Li Zhang (2011) Int J Cancer Osteopontin is a useful predictor of bone metastasis and survival in patients with locally advanced nasopharyngeal carcinoma Li Zhang (2015) Cancer Commun Efficacy of the hypoxia‑activated prodrug evofosfamide (TH‑302) in nasopharyngeal carcinoma in vitro and in vivo Li Zhang (2018) |
|
|
